Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer

Several promising targeted-therapeutics for prostate cancer (PCa), primarily affecting the androgen receptor (AR) and the PI3K/AKT/mTOR-pathway, are in various phases of development. However, despite promise, single-agent inhibitors targeting the two pathways have not shown long-term benefits, perha...

Descripción completa

Detalles Bibliográficos
Autores principales: Yadav, Shalini Singh, Li, Jinyi, Stockert, Jennifer A., O'Connor, James, Herzog, Bryan, Elaiho, Cordelia, Galsky, Matthew D., Tewari, Ashutosh Kumar, Yadav, Kamlesh Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342806/
https://www.ncbi.nlm.nih.gov/pubmed/27783994
http://dx.doi.org/10.18632/oncotarget.12771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342806/
https://www.ncbi.nlm.nih.gov/pubmed/27783994
http://dx.doi.org/10.18632/oncotarget.12771

Ejemplares similares